Table 9.
Results of applying different treatment effects on depression, irritability, and anxiety NPI subscales
| Base case | 1.33-point reduction in 3 subscales | 2-point reduction in 3 subscales | 3-point reduction in 3 subscales | 3-point reduction in ADAS-Cog | |
|---|---|---|---|---|---|
| ICER, USD | 344,425 | 295,288 | 221,067 | 148,582 | 141,619 |
| Cost outcomes, USD | |||||
| Care cost | (9,308) | (10,854) | (13,562) | (16,650) | (13,190) |
| Health outcomes | |||||
| Patient QALYs | 0.045 | 0.047 | 0.050 | 0.054 | 0.081 |
| Caregiver QALYs | 0.011 | 0.014 | 0.019 | 0.024 | 0.011 |
The reported results are differences between the treatment and placebo arms. ADAS-Cog, Alzheimer's Disease Assessment Scale-Cognitive Subscale 13; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.